Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

BACKGROUND: Tafenoquine (TQ) and primaquine (PQ) are 8-aminoquinolines (8-AQ) with anti-hypnozoite activity against vivax malaria. PQ is the only FDA-approved medicine for preventing relapsing Plasmodium vivax infection and TQ is currently in phase 3 clinical trials for the same indication. Recent s...

Descripción completa

Detalles Bibliográficos
Autores principales: St Jean, Pamela L., Xue, Zhengyu, Carter, Nick, Koh, Gavin C. K. W., Duparc, Stephan, Taylor, Maxine, Beaumont, Claire, Llanos-Cuentas, Alejandro, Rueangweerayut, Ronnatrai, Krudsood, Srivicha, Green, Justin A., Rubio, Justin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757974/
https://www.ncbi.nlm.nih.gov/pubmed/26888075
http://dx.doi.org/10.1186/s12936-016-1145-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757974/
https://www.ncbi.nlm.nih.gov/pubmed/26888075
http://dx.doi.org/10.1186/s12936-016-1145-5

Ejemplares similares